Trends Watch: Life Sciences
September 16, 2021
By Elana Margulies-Snyderman
EisnerAmper’s Trends Watch is a weekly entry to our Alternative Investments Intelligence blog, featuring the views and insights of executives from alternative investment firms. If you’re interested in being featured, please contact Elana Margulies-Snyderman.
This week, Elana talks with Miguel Fidalgo, Founder, Project X Management.
What is your outlook for investing in life sciences?
I believe that in the next 30 years we will see transformative life sciences innovation with limited precedent.
One analogy might be what we saw in technology during the last 30 years, where the advent of ubiquitous and inexpensive computing power, smart phones in every pocket, and -- most of all -- the internet transformed how we interact with the world.
Similarly, medicine will be transformed by the advent of new technologies such as gene therapies and immuno-oncology. Inevitably, tremendous wealth will be created along the way. Moderna is a great example: It now has a ~$150 billion market cap and made its founding scientists, entrepreneurs, and investors billionaires.
Where do you see the greatest opportunities and why?
Diversified exposure to transformative innovation, from therapeutics to telemedicine and beyond. Individual bets are hard to handicap, so diversification is key.
What are the biggest challenges you face and why?
Expanding the conversation with allocators on thoughtful allocation to life sciences with a time horizon of multiple years or even decades.
What keeps you up at night?
Finding new and better ways to invest seeking outstanding returns.
The views and opinions expressed above are of the interviewee only, and do not/are not intended to reflect the views of EisnerAmper.